Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a single-dose, single center, single-period, open-label, non-randomized, mass balance recovery study in healthy male subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy volunteer | Experimental | Single of 14C-PXL770 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 14C labeled PXL770 | Drug | Single administration |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mass balance recovery | Mass balance recovery of total radioactivity in all excreta: cumulative recovery (CumAe) and cumulative recovery expressed as a percentage of the dose (Cum%Ae) | From day 1 to day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| PK profile of total radioactivity | Cmax | From day 1 to day 7 |
| PK profile of PXL770 | Cmax | From day 1 to day 7 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Quotient | Nottingham | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Incidence of Treatment-Emergent Adverse Events | From day 1 to day 7 |